LCT联合EZH2检测在宫颈癌及癌前病变中的诊断价值

Diagnostic value of LCT combined with EZH2 detection in cervical cancer and precancerous lesions

目的 探讨液基细胞学检测系统(LCT)联合zeste基因增强子2(EZH2)检测对宫颈癌及癌前病变(CIN)预测的应用价值。方法 回顾性分析180例行宫颈癌筛查的妇科体检者的临床资料,所有体检者均接受LCT、EZH2及病理学检查,根据组织病理学检查结果进行分组,其中正常宫颈组织组、慢性宫颈炎组织组及CINⅠ组各30例,CINⅡ组及CINⅢ组各45例。比较LCT、EZH2单独及联合检查的检出结果及诊断效能。结果 LCT、EZH2单独及联合检查下真实宫颈癌及癌前病变患者分别为52例、51例及74例;LCT联合EZH2检查的诊断效能高于LCT、EZH2单独诊断,差异具有统计学意义(P<0.05)。结论 在临床诊断宫颈癌及癌前病变中,相比应用LCT、EZH2单独诊断,二者联合诊断可有效提高诊断效能,具有一定诊断优势。

Objective To investigate the significance of liquid-based cytology(LCT)combined with zeste enhancer 2(EZH2)in the prediction of cervical cancer and precancerous lesions(CIN).Methods The clinical data of 180 patients who underwent cervical cancer screening were retrospectively analyzed.All patients underwent LCT,EZH2 and pathological examination.According to the histopathological examination results,the patients were divided into the normal cervical tissue group,chronic cervicitis tissue group and CIN I group(30 cases),CIN II group and CINUI group(45 cases).The detection results and diagnostic efficacy of LCT and EZH2 alone and in combination were compared.Results There were 52,51 and 74 patients with real cervical cancer and precancerous lesions under LCT and EZH2 examination alone and in combination.The diagnostic efficiency of LCT combined with EZH2 was higher than that of LCT and EZH2 alone,and the difference was statistically significant(P<0.05).Conclusion In the clinical diagnosis of cervical cancer and precancerous lesions,the combined diagnosis of LCT and EZH2 can effectively improve the diagnostic efficiency and has certain diagnostic advantages compared with the single diagnosis of LCT and EZH2.